Skip to content
<title>Channels - Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025 :: FRELIP Discovery
Channels Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024
Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024
Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025
Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa
Assessment of miRNAs as transcriptional regulators in respiratory syncytial virus infection through computational analysis and molecular docking studies
Incidence and burden of respiratory syncytial virus infection in a community-based cohort o under-five years children in Nigeria.
Correction: Liquid-liquid phase separation mediated immune evasion of respiratory syncytial virus against oligoadenylate synthetase-RNase L pathway
Development and Application of a Quadruplex Real-Time RT-PCR Assay for Simultaneous Detection and Subtyping of Respiratory Syncytial Virus A and B
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025
Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026
Pediatric Respiratory Tract Infections and Circulating Influenza A Virus Subtypes
Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season
Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies - United States, October 2024-February 2025
Quantifying the role of pre-existing tissue resident cellular immunity in limiting respiratory virus transmission
Clade Ib Mpox Outbreak - Kenya, July 2024-February 2025
Reviewers for Journal of Integrated Pest Management (November 2024 to October 2025)
Dihydroorotate dehydrogenase (DHODH) regulates trophoblast syncytialization through organelle stress–induced cellular senescence
Investigating the impact of hypoxia and syncytialization on lipid nanoparticle‐mediated mRNA delivery to placental cells
Determining farm surface porcine reproductive and respiratory syndrome virus (PRRSV) contamination through viability RT-qPCR
Perioperative respiratory adverse events in children with active upper respiratory tract ...
